

DAFTAR PUSTAKA

- Abad-Zapatero, C. (2007). Ligand Efficiency Indices for Effective Drug Discovery. *Expert Opinion on Drug Discovery*, 2(4), 469–488.
- Abad-Zapatero, C., & Metz, J. T. (2005). Ligand Efficiency Indices as Guideposts for Drug Discovery. *Drug Discovery Today*, 10(7), 464–469.
- Alotaibi, N. M., Alotaibi, M. O., Alshammari, N., Adnan, M., & Patel, M. (2023). Network Pharmacology Combined with Molecular Docking, Molecular Dynamics, and In Vitro Experimental Validation Reveals the Therapeutic Potential of *Thymus vulgaris* L. Essential Oil (Thyme Oil) against Human Breast Cancer. *ACS Omega*, 8(50), 48344–48359.
- Altaf, L., Wani, S. A., Hussain, P. R., Suradkar, P., Baqual, M. F., & Bhat, A. A. (2024). Bioactive Compounds and Antioxidant Activity in Various Parts of *Morus alba* L. Cv. ichinose: A Comparative Analysis. *Discover Life*, 54(1), 7.
- Aparicio-Puerta, E., Lebrón, R., Rueda, A., Gómez-Martín, C., Giannoukakos, S., Jaspez, D., Medina, J. M., Zubkovic, A., Jurak, I., Fromm, B., Marchal, J. A., Oliver, J., & Hackenberg, M. (2019). sRNAbench and sRNAtoolbox 2019: Intuitive Fast Small RNA Profiling and Differential Expression. *Nucleic Acids Research*, 47(W1), W530–W535.
- Aydoğan, C. (2020). Recent Advances and Applications in LC-HRMS for Food and Plant Natural Products: A Critical Review. *Analytical and Bioanalytical Chemistry*, 412(9), 1973–1991.
- Bai, L., Zhou, H., Xu, R., Zhao, Y., Chinnaswamy, K., McEachern, D., Chen, J., Yang, C.-Y., Liu, Z., Wang, M., Liu, L., Jiang, H., Wen, B., Kumar, P., Meagher, J. L., Sun, D., Stuckey, J. A., & Wang, S. (2019). A Potent and Selective Small-Molecule Degradator of STAT3 Achieves Complete Tumor Regression In Vivo. *Cancer Cell*, 36(5), 498–511.e17.
- Belachew, E. B., & Sewasew, D. T. (2021). Molecular Mechanisms of Endocrine Resistance in Estrogen-Receptor-Positive Breast Cancer. *Frontiers in Endocrinology*, 12.
- Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024). Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: A Cancer Journal for Clinicians*, 74(3), 229–263.
- Burley, S. K., Bhikadiya, C., Bi, C., Bittrich, S., Chen, L., Crichlow, G. V., Christie, C. H., Dalenberg, K., Di Costanzo, L., Duarte, J. M., Dutta, S., Feng, Z., Ganesan, S., Goodsell, D. S., Ghosh, S., Green, R. K., Guranović, V., Guzenko, D., Hudson, B. P., ... Zhuravleva, M. (2021). RCSB Protein Data Bank: Powerful New Tools for Exploring 3D Structures of Biological Macromolecules for Basic and Applied Research and Education in Fundamental Biology, Biomedicine, Biotechnology, Bioengineering and Energy Sciences. *Nucleic Acids Research*, 49(D1), D437–D451.
- Cerma, K., Piacentini, F., Moschetti, L., Barbolini, M., Canino, F., Tornincasa, A., Caggia, F., Cerri, S., Molinaro, A., Dominici, M., & Omarini, C. (2023). Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges. *Biomedicine*, 11(1), 109.

- Chan, E. W. C., Wong, S. K., Tangah, J., Inoue, T., & Chan, H. T. (2020). Phenolic Constituents and Anticancer Properties of *Morus alba* (White Mulberry) Leaves. *Journal of Integrative Medicine*, 18(3), 189–195.
- Chin, C.-H., Chen, S.-H., Wu, H.-H., Ho, C.-W., Ko, M.-T., & Lin, C.-Y. (2014). CytoHubba: Identifying Hub Objects and Sub-Networks from Complex Interactome. *BMC Systems Biology*, 8(S4), S11.
- Craven, G. B., Chu, H., Sun, J. D., Carelli, J. D., Coyne, B., Chen, H., Chen, Y., Ma, X., Das, S., Kong, W., Zajdlik, A. D., Yang, K. S., Reisberg, S. H., Thompson, P. A., Lipford, J. R., & Taunton, J. (2025). Mutant-Selective AKT Inhibition Through Lysine Targeting and Neo-Zinc Chelation. *Nature*, 637(8044), 205–214.
- Daina, A., Michielin, O., & Zoete, V. (2019). SwissTargetPrediction: Updated Data and New Features for Efficient Prediction of Protein Targets of Small Molecules. *Nucleic Acids Research*, 47(W1), W357–W364.
- Del Console, P., Catalano, S., & Györfy, B. (2026). Overweight and Obesity Increase Breast Cancer Risk in Postmenopausal Women: A Meta-Analysis of 38 Observational Studies. *GeroScience*.
- Durán-Iturbide, N. A., Díaz-Eufracio, B. I., & Medina-Franco, J. L. (2020). In Silico ADME/Tox Profiling of Natural Products: A Focus on BIOFACQUIM. *ACS Omega*, 5(26), 16076–16084.
- Durrani, I. A., John, P., Bhatti, A., & Khan, J. S. (2024). Network Medicine Based Approach for Identifying The Type 2 Diabetes, Osteoarthritis and Triple Negative Breast Cancer Interactome: Finding The Hub of Hub Genes. *Heliyon*, 10(17), e36650.
- Egbuna, C., Patrick-Iwuanyanwu, K. C., Onyeike, E. N., Uche, C. Z., Ogoke, U. P., Riaz, M., Ibezim, E. N., Khan, J., Adedokun, K. A., Imodoye, S. O., Bello, I. O., & Awuchi, C. G. (2023). Wnt/ β -Catenin Signaling Pathway Inhibitors, Glycyrrhizic Acid, Solanine, Polyphyllin I, Crocin, Hypericin, Tubeimoside-1, Diosmin, and Rutin in Medicinal Plants Have Better Binding Affinities and Anticancer Properties: Molecular Docking and ADMET Study. *Food Science & Nutrition*, 11(7), 4155–4169.
- El-Hachem, N., Haibe-Kains, B., Khalil, A., Kobeissy, F. H., & Nemer, G. (2017). *AutoDock and AutoDockTools for Protein-Ligand Docking: Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1(BACE1) as a Case Study* (pp. 391–403).
- Elshazly, A. M., & Gewirtz, D. A. (2022). An Overview of Resistance to Human Epidermal Growth Factor Receptor 2 (Her2) Targeted Therapies in Breast Cancer. *Cancer Drug Resistance*, 5(2), 472–486.
- Ferraz, A. P. C. R., Figueiredo, P. de O., & Yoshida, N. C. (2024). Black Mulberry (*Morus nigra* L.): A Review of Attributes as an Anticancer Agent to Encourage Pharmaceutical Development. *Advances in Pharmacological and Pharmaceutical Sciences*, 2024(1).
- Ferreira, L., Dos Santos, R., Oliva, G., & Andricopulo, A. (2015). Molecular Docking and Structure-Based Drug Design Strategies. *Molecules*, 20(7), 13384–13421.

- Filimonov, D. A., Lagunin, A. A., Gloriovova, T. A., Rudik, A. V., Druzhilovskii, D. S., Pogodin, P. V., & Poroikov, V. V. (2014). Prediction of the Biological Activity Spectra of Organic Compounds Using the Pass Online Web Resource. *Chemistry of Heterocyclic Compounds*, 50(3), 444–457.
- Fitrianti, A. E., Wardani, N. O., Astuti, A., Anggadiredja, K., Amalia, L., Putri, R. A., & Zazuli, Z. (2025). Cardiotoxicity in Breast Cancer Therapy: Risks, Mechanisms, and Prevention Strategies. *Medical Sciences*, 13(3), 130.
- Gallardo, A., Lerma, E., Escuin, D., Tibau, A., Muñoz, J., Ojeda, B., Barnadas, A., Adrover, E., Sánchez-Tejada, L., Giner, D., Ortiz-Martínez, F., & Peiró, G. (2012). Increased Signalling of EGFR and IGF1R, and Deregulation of PTEN/PI3K/Akt Pathway are Related with Trastuzumab Resistance in HER2 Breast Carcinomas. *British Journal of Cancer*, 106(8), 1367–1373.
- Godet, I., & M. Gilkes, D. (2017). BRCA1 and BRCA2 Mutations and Treatment Strategies for Breast Cancer. *Integrative Cancer Science and Therapeutics*, 4(1).
- Grijseels, S., Vasskog, T., Heinsvig, P. J., Myhre, T. N., Hansen, T., & Mardal, M. (2024). Validation of Two LC HRMS Methods for Large-Scale Untargeted Metabolomics of Serum Samples: Strategy to Establish Method Fitness-for-Purpose. *Journal of Chromatography A*, 1732, 465230.
- Hamdan, D. I., Salah, S., Hassan, W. H. B., Morsi, M., Khalil, H. M. A., Ahmed-Farid, O. A., El-Shiekh, R. A., Nael, M. A., & Elissawy, A. M. (2022). Anticancer and Neuroprotective Activities of Ethyl Acetate Fractions from *Morus macroura* Miq. Plant Organs with Ultrapformance Liquid Chromatography-Electrospray Ionization-Tandem Mass Spectrometry Profiling. *ACS Omega*, 7(18), 16013–16027.
- Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of Cancer: The Next Generation. *Cell*, 144(5), 646–674. <https://doi.org/10.1016/j.cell.2011.02.013>
- Harbeck, N., Penault-Llorca, F., Cortes, J., Gnant, M., Houssami, N., Poortmans, P., Ruddy, K., Tsang, J., & Cardoso, F. (2019). Breast Cancer. *Nature Reviews Disease Primers*, 5(1), 66.
- Heinsvig, P. J., Noble, C., Dalsgaard, P. W., & Mardal, M. (2023). Forensic Drug Screening by Liquid Chromatography Hyphenated with High-Resolution Mass Spectrometry (LC-HRMS). *TrAC Trends in Analytical Chemistry*, 162, 117023.
- Helguera, A., Combes, R., Gonzalez, M., & Cordeiro, M. N. (2008). Applications of 2D Descriptors in Drug Design: A DRAGON Tale. *Current Topics in Medicinal Chemistry*, 8(18), 1628–1655.
- Hopkins, A. L., Groom, C. R., & Alex, A. (2004). Ligand Efficiency: A Useful Metric for Lead Selection. *Drug Discovery Today*, 9(10), 430–431.
- Hopkins, A. L., Keserü, G. M., Leeson, P. D., Rees, D. C., & Reynolds, C. H. (2014). The Role of Ligand Efficiency Metrics in Drug Discovery. *Nature Reviews Drug Discovery*, 13(2), 105–121.
- Hu, X., Zhang, Q., Xing, W., & Wang, W. (2022). Role of MicroRNA/lncRNA Intertwined With the Wnt/ β -Catenin Axis in Regulating the Pathogenesis of Triple-Negative Breast Cancer. *Frontiers in Pharmacology*, 13.

- Huang, B., Huang, C., Zhu, L., Xie, L., Wang, Y., & Zhu, N. (2021). Exploring the Pharmacological Mechanisms of *Tripterygium wilfordii* Hook F against Cardiovascular Disease Using Network Pharmacology and Molecular Docking. *BioMed Research International*, 2021(1).
- Huria, N., A. Saraf, A., Lobo Padinjarekutt, D., Gaikwad, L., Mourya, N., Deo, D., V.U. Tanpathak, S., & Burande, S. (2024). The Biomarker Flavonoid “Rutin” in *Morus* Species: Isolation, Identification, and Characterization. In *Recent Advances in Phytochemical Research* (Metrics Overview).
- Jamshidi, S., Eghbalian, A., Shojaei, S., Taherkhani, A., & Feizi-Dehnayebi, M. (2025). Flavonoids as Promising Akt1 Inhibitors in Cancer Medicine: Insights From Molecular Docking, Dynamics, DFT Calculations, and In Vitro Validation. *Cancer Reports*, 8(8).
- Kaddah, M. M. Y., El Demellawy, M. A., & Talaat, W. (2025). Comprehensive Analytical Approaches: The Use of LC-MS and IC-MS in Modern Pharmaceutical and Biomedical Sciences. *Microchemical Journal*, 216, 114780.
- Katoch, S., Chauhan, S. S., & Kumar, V. (2021). A Review on Genetic Algorithm: Past, Present, and Future. *Multimedia Tools and Applications*, 80(5), 8091–8126.
- Kessler, D., Mayer, M., Zahn, S. K., Zeeb, M., Wöhrle, S., Bergner, A., Bruchhaus, J., Ciftci, T., Dahmann, G., Dettling, M., Döbel, S., Fuchs, J. E., Geist, L., Hela, W., Kofink, C., Kousek, R., Moser, F., Puchner, T., Rumpel, K., ... Böttcher, J. (2021). Getting a Grip on the Undrugged: Targeting β -Catenin with Fragment-Based Methods. *ChemMedChem*, 16(9), 1420–1424.
- Kim, S., Chen, J., Cheng, T., Gindulyte, A., He, J., He, S., Li, Q., Shoemaker, B. A., Thiessen, P. A., Yu, B., Zaslavsky, L., Zhang, J., & Bolton, E. E. (2023). PubChem 2023 Update. *Nucleic Acids Research*, 51(D1), D1373–D1380.
- Lenski, M. (2025). High-Resolution Mass Spectrometry for Metabolomics. *Toxicologie Analytique et Clinique*, 37(1), S64.
- Li, Q., Qin, Z., Wang, Q., Xu, T., Yang, Y., & He, Z. (2019). Applications of Genome Editing Technology in Animal Disease Modeling and Gene Therapy. In *Computational and Structural Biotechnology Journal* (Vol. 17, pp. 689–698). Elsevier B.V.
- Li, S., So, T., Tang, G., Tan, H.-Y., Wang, N., Ng, B. F. L., Chan, C. K. W., Yu, E. C.-L., & Feng, Y. (2020). Chinese Herbal Medicine for Reducing Chemotherapy-Associated Side-Effects in Breast Cancer Patients: A Systematic Review and Meta-Analysis. *Frontiers in Oncology*, 10.
- Liu, W., Chu, Z., Yang, C., Yang, T., Yang, Y., Wu, H., & Sun, J. (2023). Discovery of Potent STAT3 Inhibitors using Structure-Based Virtual Screening, Molecular Dynamic Simulation, and Biological Evaluation. *Frontiers in Oncology*, 13.
- Loibl, S., & Gianni, L. (2017). HER2-Positive Breast Cancer. *The Lancet*, 389(10087), 2415–2429.
- Long, L., Fei, X., Chen, L., Yao, L., & Lei, X. (2024). Potential Therapeutic Targets of The JAK2/STAT3 Signaling Pathway in Triple-Negative Breast Cancer. *Frontiers in Oncology*, 14.

- Lv, Y., Mou, Y., Su, J., Liu, S., Ding, X., Yuan, Y., Li, G., & Li, G. (2023). The Inhibitory Effect and Mechanism of Resina Draconis on The Proliferation of MCF-7 Breast Cancer Cells: A Network Pharmacology-Based Analysis. *Scientific Reports*, 13(1), 3816.
- Ma, J., Qin, L., & Li, X. (2020). Role of STAT3 Signaling Pathway in Breast Cancer. *Cell Communication and Signaling*, 18(1), 33.
- Maitisha, G., Zhou, J., Zhao, Y., Han, S., Zhao, Y., Abliz, A., & Liu, G. (2023). Network Pharmacology-Based Approach to Investigate The Molecular Targets of Essential Oil Obtained from Lavender for Treating Breast Cancer. *Heliyon*, 9(11), e21759.
- Mardhiyah, A. K., Putri, D. H., Violita, V., Anhar, A., Hafids, A., Sofani, A., & Susanti, T. (2023). *Phytochemical Characterization of Bioactive Compounds on Ethanol Extracts Fermentation Products of Isolate BJDTA21 Endophytic Bacterial Andalas* (pp. 318–323).
- Maurer, H. H. (2021). Hyphenated High-Resolution Mass Spectrometry The “All-in-One” Device in Analytical Toxicology? *Analytical and Bioanalytical Chemistry*, 413(9), 2303–2309.
- Md Amin, N. A., Sheikh Abdul Kadir, S. H., Arshad, A. H., Abdul Aziz, N., Abdul Nasir, N. A., & Ab Latip, N. (2022). Are Vitamin E Supplementation Beneficial for Female Gynaecology Health and Diseases? *Molecules*, 27(6), 1896.
- Memete, A. R., Timar, A. V., Vuscan, A. N., Miere (Groza), F., Venter, A. C., & Vicas, S. I. (2022). Phytochemical Composition of Different Botanical Parts of Morus Species, Health Benefits and Application in Food Industry. *Plants*, 11(2), 152.
- Monita, Y. (2022). *Induksi Akar Tanaman Andalas (Morus macroura Miq.) dengan Berbagai Konsentrasi Iba Secara In Vitro*.
- Motta, J. M., Hassan, H., & Ibrahim, S. A. (2023). Revisiting the Syndecans: Master Signaling Regulators with Prognostic and Targetable Therapeutic Values in Breast Carcinoma. *Cancers*, 15(6), 1794.
- Nicolis, O., De Los Angeles, D., & Taramasco, C. (2024). A Contemporary Review of Breast Cancer Risk Factors and The Role of Artificial Intelligence. *Frontiers in Oncology*, 14.
- Noor, F., Tahir ul Qamar, M., Ashfaq, U. A., Albutti, A., Alwashmi, A. S. S., & Aljasir, M. A. (2022). Network Pharmacology Approach for Medicinal Plants: Review and Assessment. *Pharmaceuticals*, 15(5), 572.
- Nuratika, E., Aseny, N., Syamsuardi, Nurainas, Fitmawati, & Friardi. (2020). Clarification of Sumatran Mulberry (*Morus macroura* var. *macroura*, Moraceae) from West Sumatra, Indonesia using Nucleus Ribosomal ITS (Internal Transcribed Spacer) Gene. *Indian Journal Of Agricultural Research*, (OF).
- Osborne, A., Adnani, Q. E. S., & Ahinkorah, B. O. (2025). Breast Cancer Incidence in Indonesia: A Sex-Disaggregated Analysis Using WHO Health Equity Assessment Toolkit Data. *BMC Cancer*, 25(1), 986.
- Pagadala, N. S., Syed, K., & Tuszynski, J. (2017). Software for Molecular Docking: A Review. *Biophysical Reviews*, 9(2), 91–102.

- Pinzi, L., & Rastelli, G. (2019). Molecular Docking: Shifting Paradigms in Drug Discovery. *International Journal of Molecular Sciences*, 20(18), 4331.
- Prasetyo, W. E., Purnomo, H., Sadrini, M., Wibowo, F. R., Firdaus, M., & Kusumaningsih, T. (2023). Identification of Potential Bioactive Natural Compounds from Indonesian Medicinal Plants against 3-Chymotrypsin-Like Protease (3CL) of SARS-CoV-2: Molecular Docking, ADME/T, Molecular Dynamic Simulations, and DFT Analysis. *Journal of Biomolecular Structure and Dynamics*, 41(10), 4467–4484.
- Raman, S., Ganeshan, A. K. G., Chen, C., Jin, C., Li, S.-H., Chen, H.-J., & Gui, Z. (2016). In Vitro and In Vivo Antioxidant Activity of Flavonoid Extracted from Mulberry Fruit (*Morus alba* L.). *Pharmacognosy Magazine*, 12(46), 128.
- Rascio, F., Spadaccino, F., Rocchetti, M. T., Castellano, G., Stallone, G., Netti, G. S., & Ranieri, E. (2021). The Pathogenic Role of PI3K/AKT Pathway in Cancer Onset and Drug Resistance: An Updated Review. *Cancers*, 13(16), 3949.
- Rochat, B. (2016). From Targeted Quantification to Untargeted Metabolomics: Why LC-High-Resolution-MS will Become A Key Instrument in Clinical Labs. *TrAC Trends in Analytical Chemistry*, 84, 151–164.
- Sha, R., Kong, X., Li, X., & Wang, Y. (2024). Global Burden of Breast Cancer and Attributable Risk Factors in 204 Countries and Territories, from 1990 to 2021: Results from the Global Burden of Disease Study 2021. *Biomarker Research*, 12(1), 87.
- Sohel Rana, M., Mijanur Rahman, M., Baker, J., Houssami, N., Qin Yu, X., & Luke Marinovich, M. (2025). Association of Lifestyle Factors with Breast Cancer Incidence: An Overview of Systematic Reviews. *Chinese Journal of Cancer Research*, 37(4), 575–591.
- Stelzer, G., Rosen, N., Plaschkes, I., Zimmerman, S., Twik, M., Fishilevich, S., Stein, T. I., Nudel, R., Lieder, I., Mazor, Y., Kaplan, S., Dahary, D., Warshawsky, D., Guan-Golan, Y., Kohn, A., Rappaport, N., Safran, M., & Lancet, D. (2016). The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. *Current Protocols in Bioinformatics*, 54(1).
- Stordal, B., Harvie, M., Antoniou, M. N., Bellingham, M., Chan, D. S. M., Darbre, P., Karlsson, O., Kortenkamp, A., Magee, P., Mandriota, S., Silva, E., Turner, J. E., Vandenberg, L. N., & Evans, D. G. (2024). Breast Cancer Risk and Prevention in 2024: An Overview from the Breast Cancer UK- Breast Cancer Prevention Conference. *Cancer Medicine*, 13(18).
- Szklarczyk, D., Gable, A. L., Nastou, K. C., Lyon, D., Kirsch, R., Pyysalo, S., Doncheva, N. T., Legeay, M., Fang, T., Bork, P., Jensen, L. J., & von Mering, C. (2021). The STRING Database in 2021: Customizable Protein–Protein Networks, and Functional Characterization of User-Uploaded Gene/Measurement Sets. *Nucleic Acids Research*, 49(D1), D605–D612.
- Taman Digital Fakultas Pertanian Universitas Andalas. (2026). *Andalas (Morus macroura* Miq.).
- To, S. Q., Dmello, R. S., Richards, A. K., Ernst, M., & Chand, A. L. (2022). STAT3 Signaling in Breast Cancer: Multicellular Actions and Therapeutic Potential. *Cancers*, 14(2), 429.

- Vigo-Díaz, N., López-Cortés, R., Velo-Helene, I., Rodríguez-Silva, L., & Núñez, C. (2025). Proteoglycans in Breast Cancer: Friends and Foes. *Biomolecules*, 15(12), 1688.
- Waks, A. G., & Winer, E. P. (2019). Breast Cancer Treatment. *JAMA*, 321(3), 288.
- WHO Classification of Tumours Editorial Board. (2019). *Breast Tumours* (5th ed.). International Agency for Research on Cancer (IARC).
- Winkler, M.-C., & Hetjens, S. (2024). Risk Factors and Preventive Measures for Breast Cancer. *Journal of Clinical Medicine*, 13(16), 4610.
- Wu, H., Wang, J., Geng, T., Yao, Y., Lin, P., Wang, S., & Xu, L. (2026). A High-Quality Chromosome-Level Genome Assembly of The Low Chilling Requirement Mulberry, *Morus macroura*. *Scientific Data*, 13(1), 458.
- Xu, M., Zhang, Y., Mei, R., Xue, T., Cai, H., Zhou, Y., & Guo, J. (2026). Integrated Network Pharmacology and Machine Learning to Reveal the Mechanisms of Schisandrin A Against Triple-Negative Breast Cancer. *Journal of Cellular and Molecular Medicine*, 30(11).
- Xu, X., Zhang, M., Xu, F., & Jiang, S. (2020). Wnt Signaling in Breast Cancer: Biological Mechanisms, Challenges and Opportunities. *Molecular Cancer*, 19(1), 165.
- Yellapu, N. K., Pei, D., Nissen, E., Thompson, J. A., & Koestler, D. C. (2023). Comprehensive Exploration of JQ1 and GSK2801 Targets in Breast Cancer Using Network Pharmacology and Molecular Modeling Approaches. *Computational and Structural Biotechnology Journal*, 21, 3224–3233.
- Yuan, J., Yang, L., Li, Z., Zhang, H., Wang, Q., Huang, J., Wang, B., Mohan, C. D., Sethi, G., & Wang, G. (2023). The Role of The Tumor Microenvironment in Endocrine Therapy Resistance in Hormone Receptor-Positive Breast Cancer. *Frontiers in Endocrinology*, 14.
- Zhai, X., Chen, X., Xiao, X., & Wu, L. (2025). Application of Network Pharmacology in Traditional Chinese Medicine for The Treatment of Cardiac Diseases. *Frontiers in Pharmacology*, 16.
- Zhang, M., Ma, J., Zeng, F.-Y., & Hou, X.-H. (2024). Network pharmacology combined with molecular docking revealed the potential targets of *Coridius chinensis* in prostate cancer treatment. *World Journal of Clinical Cases*, 12(27), 6094–6104.
- Zhao, W., Wang, B., & Li, S. (2024). Network Pharmacology for Traditional Chinese Medicine in Era of Artificial Intelligence. *Chinese Herbal Medicines*, 16(4), 558–560.